STEPHANIE BADON: Open Payments
NPI 1649936956 · NEW IBERIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$732 in 42 payments from 12 companies in 2025. Trend: 2023 $1,305 · 2024 $1,071 · 2025 $732
Food & beverage: $732
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $212 |
| Otsuka America Pharmaceutical, Inc. | 9 | $146 |
| Alkermes, Inc. | 3 | $54 |
| ABBVIE INC. | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Braeburn Inc. | 2 | $41 |
| Janssen Pharmaceuticals, Inc | 2 | $37 |
| Axsome Therapeutics, Inc. | 2 | $35 |
Products named: CAPLYTA, ABILIFY ASIMTUFII, ARISTADA, VRAYLAR, Qelbree, FANAPT, BRIXADI, INVEGA SUSTENNA.
Industry payments across LA — which companies pay providers there.
